MeSH term
Frequency | Condition_Probility | Child | 18 | 0.0 |
Child, Preschool | 16 | 0.0 |
Dystroglycans | 10 | 20.0 |
Humans | 59 | 0.0 |
Immunohistochemistry | 5 | 0.0 |
Infant | 10 | 0.0 |
Research Support, Non-U.S. Gov't | 34 | 0.0 |
Amino Acid Sequence | 4 | 0.0 |
Base Sequence | 3 | 0.0 |
Blotting, Western | 3 | 0.0 |
Cell Line | 3 | 0.0 |
DNA Mutational Analysis | 4 | 0.0 |
Female | 30 | 0.0 |
Gene Expression | 2 | 0.0 |
Male | 33 | 0.0 |
Molecular Sequence Data | 7 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Pedigree | 11 | 0.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Adult | 19 | 0.0 |
Cytoskeletal Proteins/*metabolism | 3 | 1.0 |
Genotype | 8 | 0.0 |
Glycosylation | 8 | 0.0 |
Membrane Glycoproteins/*metabolism | 2 | 0.0 |
Adolescent | 12 | 0.0 |
Brain/*abnormalities | 8 | 28.0 |
Linkage (Genetics)/genetics | 3 | 1.0 |
Lod Score | 4 | 0.0 |
Phenotype | 3 | 0.0 |
Evoked Potentials, Visual | 3 | 13.0 |
Magnetic Resonance Imaging | 6 | 0.0 |
Cell Movement | 2 | 0.0 |
Cells, Cultured | 9 | 0.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Lipopolysaccharides/pharmacology | 2 | 0.0 |
Methylene Blue/pharmacology | 2 | 25.0 |
Nitroprusside/pharmacology | 3 | 4.0 |
Chromosome Mapping | 5 | 0.0 |
Eye Abnormalities/genetics | 2 | 7.0 |
Infant, Newborn | 2 | 0.0 |
Aged | 3 | 0.0 |
Dystrophin/metabolism | 2 | 20.0 |
Membrane Glycoproteins/metabolism | 2 | 0.0 |
Middle Aged | 10 | 0.0 |
Animals | 13 | 0.0 |
Muscular Dystrophies/*congenital/genetics/*metabolism | 2 | 100.0 |
Protein Binding | 2 | 0.0 |
Enzyme Activation | 2 | 0.0 |
Epoxy Compounds/*toxicity | 5 | 25.0 |
Glutathione Transferase/*genetics | 3 | 0.0 |
In Vitro | 3 | 0.0 |
Isoenzymes/*genetics | 3 | 0.0 |
Lymphocytes/*drug effects | 3 | 7.0 |
*Sister Chromatid Exchange | 3 | 9.0 |
Haplotypes | 2 | 0.0 |
*Linkage (Genetics) | 2 | 0.0 |
Muscular Dystrophies/*genetics | 2 | 2.0 |
Syndrome | 8 | 0.0 |
Genes, Recessive | 2 | 0.0 |
Dose-Response Relationship, Drug | 4 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
Sister Chromatid Exchange/*drug effects | 2 | 6.0 |
*Aneuploidy | 2 | 2.0 |
Lymphocytes/*drug effects/ultrastructure | 2 | 22.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 6 | 0.0 |
*Adaptation, Physiological | 2 | 3.0 |
Mutagens/*toxicity | 3 | 2.0 |
Mice | 6 | 0.0 |
Pregnancy | 2 | 0.0 |
Kinetics | 2 | 0.0 |
Molsidomine/analogs & derivatives/pharmacology | 2 | 14.0 |
Nitroglycerin/pharmacology | 2 | 11.0 |
Penicillamine/analogs & derivatives/pharmacology | 2 | 14.0 |
Rats | 3 | 0.0 |
S-Nitroso-N-Acetylpenicillamine | 2 | 16.0 |
Vasodilator Agents/*pharmacology | 2 | 4.0 |
Alleles | 2 | 0.0 |
Brain/*abnormalities/pathology | 2 | 18.0 |
Tomography, X-Ray Computed | 3 | 0.0 |
Eye Abnormalities/*genetics | 2 | 5.0 |
*Carbamates | 2 | 25.0 |
Comparative Study | 6 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
*Micronucleus Tests | 2 | 40.0 |
*Eye Abnormalities | 3 | 75.0 |
Myopia/etiology | 2 | 66.0 |
Optic Atrophy/etiology | 2 | 100.0 |
Eye Abnormalities/*diagnosis/genetics | 2 | 100.0 |
Rabbits | 2 | 0.0 |
Electroencephalography | 2 | 0.0 |
English Abstract | 4 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Mutation | 2 | 0.0 |
Reaction Time/physiology | 2 | 2.0 |
Brain/pathology | 2 | 0.0 |
Ligands | 2 | 0.0 |
